Oncolytics Biotech, Inc. (USA)  

(Public, OTCMKTS:ONCYF)   Watch this stock  
Find more results for NASDAQ:ONCY
-0.037 (-9.30%)
Delayed:   2:25PM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.35 - 0.40
52 week 0.24 - 0.58
Open 0.40
Vol / Avg. 150,050.00/174,843.00
Mkt cap 42.18M
P/E     -
Div/yield     -
EPS -0.09
Shares 119.56M
Beta 1.69
Inst. own 1%
Aug 4, 2016
Q2 2016 Oncolytics Biotech Inc Earnings Release (Estimated) Add to calendar
May 6, 2016
Q1 2016 Oncolytics Biotech Inc Earnings Release
Mar 11, 2016
Q4 2015 Oncolytics Biotech Inc Earnings Release

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -63.93% -61.57%
Return on average equity -71.38% -71.30%
Employees 22 -
CDP Score - -


Suite 210, 1167 Kensington Crescent NW
+1-403-6707377 (Phone)
+1-403-2830858 (Fax)

Website links


Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

Officers and directors

Bradley G. Thompson Ph.D. Executive Chairman of the Board, President, Chief Executive Officer
Kirk J. Look Chief Financial Officer
Matthew C. Coffey Ph.D. Chief Operating Officer, Director
George M. Gill M.D. Senior Vice President - Regulatory Affairs & Chief Safety Officer
Alan J. Tuchman M.D. Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs
Age: 68
Mary Ann Dillahunty J.D. Vice President - Intellectual Property
Angela Frances Holtham Director
Edwin Levy Ph.D. Director
J. Mark Lievonen Director
Linda M. O. Hohol Independent Director
Age: 62